SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH ® (palopegteriparatide) by the Therapeutic Goods ...

Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical ...

Based on the revised histological diagnosis of extraskeletal Ewing sarcoma, she underwent subsequent chemotherapy consisting of vinblastine, ifosfamide, and cisplatin (VeIP) for 7 cycles (5 months), ...